Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect of LEO 152020 in Healthy Adults
NCT04203836Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of JW1601 in atopic dermatitis (AD) (2 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoints: Maximum Plasma Concentration at Day 8 and Area Under the Curve from time zero to infinity at Day 8. Started Jan 2020; status: completed.
02
Drugs
JW1601
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04203836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203836.